Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

다국어 초록 (Multilingual Abstract)

Background/Aims: We investigated the efficacy and toxicity of a weekly schedule of docetaxel and cisplatin as a first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Methods: In this study, 18 patients with previously diagnosed R/M HNSCC were treated with combination chemotherapy of weekly docetaxel 35 mg/m2 (day 1 and 8) and cisplatin 70 mg/m2 (day 1) as first-line chemotherapy, repeated every 3 weeks.
Results: Partial response and stable disease were observed in six patients (33.3%; 95% confidence interval [CI], 11.1% to 55.6%) and six patients (33.3%; 95% CI, 11.1% to 55.6%), respectively. The median overall survival and progression-free survival were 11.26 months (95% CI, 8.87 to 15.83) and 5.68 months (95% CI, 4.80 to 6.51), respectively. The major toxicity was grade 1/2 anemia (50%). Grade 3/4 neutropenia was observed in one patient (5.6%). Among the non-hematologic toxicities, grade 1/2 hepatotoxicity was most common (22.2%), and grade 3/4 infection was observed in one patient (5.6%). There was no treatment-related mortality.
Conclusions: For patients with R/M HNSCC, a cisplatin and weekly docetaxel regimen showed high efficacy with tolerable toxicity as a first-line treatment.

참고문헌 (Reference)

1 Okamoto H, "Weekly docetaxel treatment for head and neck cancer" 32 : 1915-1918, 2005

2 Specenier P, "Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck" 34 : 472-477, 2011

3 Hitt R, "Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck" 106 : 106-111, 2006

4 Cho BC, "Weekly docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck" 65 : 27-32, 2009

5 Briasoulis E, "Weekly docetaxel in minimally pretreated cancer patients : a dose-escalation study focused on feasibility and cumulative toxicity of long-term administration" 10 : 701-706, 1999

6 Hong AM, "Use of cyclin D1in conjunction with human papillomavirus status to predict outcome in oropharyngeal cancer" 128 : 1532-1545, 2011

7 Miyata M, "The influence of granisetron on the pharmacokinetics and pharmacodynamics of docetaxel in Asian lung cancer patients" 12 : 69-72, 2006

8 Lassen P, "The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer : evaluation of the randomised DAHANCA 6&7 trial" 100 : 49-55, 2011

9 "The World Cancer Report: the major findings" 11 : 177-179, 2003

10 Hong A, "Relationships between epidermal growth factor receptor expression and human papillomavirus status as markers of prognosis in oropharyngeal cancer" 46 : 2088-2096, 2010

11 Haddad RI, "Recent advances in head and neck cancer" 359 : 1143-1154, 2008

12 Forastiere AA, "Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck : a Southwest Oncology Group study" 10 : 1245-1251, 1992

13 Deng Z, "Prognostic value of human papillomavirus and squamous cell carcinoma antigen in head and neck squamous cell carcinoma" 103 : 2127-2134, 2012

14 Rischin D, "Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02phase III trial" 28 : 4142-4148, 2010

15 Charles KA, "Predicting the toxicity of weekly docetaxel in advanced cancer" 45 : 611-622, 2006

16 Hainsworth JD, "Practical aspects of weekly docetaxel administration schedules" 9 : 538-545, 2004

17 Glisson BS, "Phase II trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck" 20 : 1593-1599, 2002

18 Kafri Z, "Phase II study of gemcitabine and docetaxel combination in patients with previously treated recurrent or metastatic squamous cell carcinoma of the head and neck" 2012 : 159568-, 2012

19 Specht L, "Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck" 11 : 845-849, 2000

20 Cho SH, "Phase II study of a biweekly schedule of docetaxel and cisplatin in patients with metastatic non-small cell lung cancer" 69 : 94-98, 2010

21 Bosch TM, "Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel" 12 : 5786-5793, 2006

22 Fayette J, "Paclitaxel is effective in relapsed head and neck squamous cell carcinoma : a retrospective study of 66 patients at a single institution" 21 : 553-558, 2010

23 Therasse P, "New guidelines to evaluate the response to treatment in solid tumors" 92 : 205-216, 2000

24 Pfister DG, "NCCN practice guidelines for head and neck cancers" 14 : 163-194, 2000

25 Benson AB 3rd, "NCCN clinical practice guidelines in oncology : hepatobiliary cancers" 7 : 350-391, 2009

26 Kotwall C, "Metastatic patterns in squamous cell cancer of the head and neck" 154 : 439-442, 1987

27 Hannisdal K, "Human papillomavirus(HPV)-positive tonsillar carcinomas are frequent and have a favourable prognosis in males in Norway" 130 : 293-299, 2010

28 Ang KK, "Human papillomavirus and survival of patients with oropharyngeal cancer" 363 : 24-35, 2010

29 Chaturvedi AK, "Human papillomavirus and rising oropharyngeal cancer incidence in the United States" 29 : 4294-4301, 2011

30 Zbaren P, "Frequency and sites of distant metastases in head and neck squamous cell carcinoma. An analysis of 101 cases at autopsy" 113 : 762-764, 1987

31 Goh BC, "Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies" 20 : 3683-3690, 2002

32 Andl T, "Etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control" 58 : 5-13, 1998

33 Kucukzeybek Y, "Docetaxel and platinum combination chemotherapy in locally advanced or metastatic head and neck cancer" 13 : 199-203, 2008

34 Argiris A, "Docetaxel and irinotecan in recurrent or metastatic head and neck cancer : a phase 2 trial of the Eastern Cooperative Oncology Group" 115 : 4504-4513, 2009

35 Schoffski P, "Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group" 10 : 119-122, 1999

36 Caponigro F, "Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck : a phase II study of the Southern Italy Cooperative Oncology Group(SICOG)" 12 : 199-202, 2001

37 Luo Z, "Continuous infusion of 5-FU with split-dose cisplatin : an effective treatment for advanced squamous-cell carcinoma of the head and neck" 34 : E8-E13, 2011

38 Sethi S, "Characteristics and survival of head and neck cancer by HPV status : a cancer registry-based study" 131 : 1179-1186, 2012

39 Jemal A, "Cancer statistics, 2008" 58 : 71-96, 2008

40 Huang YC, "A study using ifosfamide and etoposide in patients with cisplatin-refractory recurrent or metastatic head and neck squamous cell carcinoma" 41 : 630-636, 2011

41 Chen YM, "A randomized trial of different docetaxel schedules in nonsmall cell lung cancer patients who failed previous platinum-based chemotherapy" 129 : 1031-1038, 2006

42 Kim YS, "A randomized phase II study of weekly docetaxel/cisplatin versus weekly docetaxel/oxaliplatin as first-line therapy for patients with advanced gastric cancer" 73 : 163-169, 2014

43 Ji JH, "A prospective multicentre phase II study of cisplatin and weekly docetaxel as first-line treatment for recurrent or metastatic nasopharyngeal cancer(KCSG HN07-01)" 48 : 3198-3204, 2012

44 Jacobs C, "A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck" 10 : 257-263, 1992

45 Won YW, "A phase II study of combination chemotherapy with capecitabine and cisplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck" 22 : 417-423, 2011

46 Tabernero J, "A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer" 15 : 1358-1365, 2004